It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: MonkeyBalls2
a reply to: angelchemuel
No ones talking about forcing the vaccine on anyone in Africa or Asia.
Just to let those who want to have hit, get it.
We haven't been doing a very good job so far, and there should be overproduction by now.
"While there are no documented studies yet involving self-spreading vaccines for use in humans, even before the coronavirus pandemic struck, it was something UK government officials were exploring as a viable option for tackling seasonal flu.
In a 2019 paper prepared for the Department of Health and Social Care, officials mapped out a hypothetical case to show how releasing a self-spreading flu vaccine into the UK population could be used to reduce illness and save lives."
The research is being subsidised by high-profile funding organisations, including the U.S. National Institutes of Health (the country’s main medical research agency).
Medicago and GlaxoSmithKline announced that Health Canada has granted approval for Covifenz, COVID-19 vaccine, (plant-based virus-like particles [VLP], recombinant, adjuvanted). This vaccine is indicated for active immunization to prevent COVID‑19 caused by severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) in individuals 18 to 64 years of age. The vaccination regimen calls for two doses given intramuscularly 21 days apart.
The Canadian approval of Covifenz was based on positive phase III data which showed that Covifenz demonstrated 71% efficacy against all variants of the virus. Against the Gamma variant, the vaccine was 88.6% effective, and 75.3% effective against the Delta variant. No cases of the Alpha, Lambda and Mu variants were observed in the vaccinated group while 12 cases were observed in the placebo group, the companies said. The Omicron variant was not circulating during the time the study was being conducted, both GSK and Medicago said.
Medicago and GSK submitted data to Health Canada on a rolling submission beginning in April 2021.